What do the terms HIV and AIDS mean?
HIV (human immunodeficiency virus) and AIDS (acquired immunodeficiency syndrome) are often spoken of as the same, but they are not:
- HIV is a virus that attacks the body’s immune system and weakens its ability to fight off infection.
- AIDS is an advanced stage of HIV infection in which the immune system is so weak that patients are likely to get infections and/or cancers that typically do not affect people with normal immune systems.
- So, while every patient with AIDS has an HIV infection, not all HIV-infected patients have AIDS. Early diagnosis and treatment of HIV infection can prevent patients from getting AIDS.
How do children and youth get HIV infection?
- HIV is spread person to person through contact with blood and certain other bodily fluids.
- Most HIV-infected children acquire infection from their HIV-infected mothers before or at the time of delivery. In HIV-infected mothers who have access to HIV care and take medicines, the chances of the baby getting infected are low (less than 1 in 100).
- Sexually active teens can acquire infection by engaging in unprotected sex. The Centers for Disease Control and Prevention (CDC) notes that about one in four new HIV infections in the United States is in youth 13 to 24 years of age. Using barrier protection, such as a condom, not only prevents HIV infection but also prevents other sexually transmitted diseases, such as syphilis, Hepatitis B and gonorrhea.
- HIV is not spread by shaking hands, touching or other causal contact with an HIV-infected patient
What are the symptoms of HIV infection in children and youth?
- Most HIV-infected patients have no symptoms for months to years.
- Every pregnant woman should be offered an HIV test; all children born to HIV-infected women should receive medicines to prevent HIV infection and should have follow-up testing for HIV infection.
- The CDC recommends that everyone between the ages of 13 and 64 should be tested at least once for HIV, regardless of whether they have symptoms.
- Some HIV-infected children may have pneumonia or failure to gain weight.
- Some youth may have a brief “mono-like illness” with fever, sore throat and swollen neck glands in the days following infection.
How is HIV infection diagnosed in children and youth?
- Children born to HIV-infected mothers are followed closely and blood tests done to ensure that they are not HIV-infected.
- In youth and adults in the United States, HIV infection can be diagnosed with simple, easily accessible blood or oral swab tests. Quick, easy and free, HIV tests are available through the health department and other community agencies. Every effort should be made to help people become aware of their diagnosis and to get treatment.
How is HIV infection in children and youth treated?
- There are many medicines available to treat HIV. These medicines are called antiretrovirals (ARVs) and may be combined, sometimes in one pill to be taken once a day. The treatment is similar to the treatment of other chronic diseases such as diabetes or high blood pressure. Until a cure for HIV is found, antiretroviral therapy (ART) must be taken as prescribed.
- Like people with other chronic diseases, HIV-infected patients who are in care and receiving treatment are living longer, healthier lives.
When was the St. Jude HIV program started and what does it offer?
In 1987, St. Jude founder Danny Thomas declared AIDS a catastrophic disease of children. It was then that HIV/AIDS became a research priority of St. Jude. Since that time, the St. Jude Department of Infectious Diseases has developed a broad, multidisciplinary pediatric program called the Pediatric AIDS Clinical Trials Unit (PACTU), which has been designated a "Center of Excellence" by the Robert Wood Johnson Foundation. The St. Jude HIV program for children and youth includes the following:
- A broad, dedicated team: The staff consists of doctors, nurse practitioners, nurses, social workers, pharmacists, a psychiatrist, a psychologist, a chaplain and a Child Life specialist. All of these people specialize in pediatric and youth-specific issues.
- Continuity of HIV care: HIV-infected patients from birth through 21 years of age are accepted in the program and are provided the latest, recommended HIV care. Patients are supported through 24 years of age and then transition to an adult care provider of the patient’s choice. A health care provider can refer an HIV-infected child or youth to St. Jude.
- A respected research program: The St. Jude HIV program is a well-recognized research center and takes part in numerous National Institutes of Health (NIH) and pharmaceutical industry studies. Supported by the NIH, St. Jude is a site for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the Adolescent Trials Network (ATN) and the Pediatric HIV/AIDS Cohort Study (PHACS).
- Clinical trials: Through clinical trials, patients in the St. Jude HIV program have access to cutting-edge research including new drugs in development.
- A commitment to the community: The St. Jude HIV clinical staff is committed to the cause of HIV education and prevention in the community. Our doctors, nurse practitioners and social workers provide HIV education and prevention presentations throughout the community and local school system.
For more information about HIV in the Memphis community, visit: www.hivmemphis.org.
What current clinical trials are available for HIV infection?
Please contact us directly to discuss a patient’s condition. There may be clinical trials available that are not listed.
PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- The subject has been enrolled on IMPAACT P1025.
Comparing the Effectiveness of Two Alcohol+Adherence Interventions For HIV+ Youth (Healthy Choices 2; HC2)
This is a non-therapeutic clinical trial that is only open to St. Jude patients.
- Participant receives services at St. Jude.
- Participant has HIV-1 Infection.
- Participant is between the ages of 16 years and 24 years.
- Participant has been offered a prescription for antiretroviral (ARV) medications.
- Participant is able to understand, read, and speak English.
- Participant has used alcohol in the last 12 weeks prior to screening.
ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects
A Phase 2/3 multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects
- Participant does not have life expectancy of less than 1 year.
- Participant does not have history of significant drug sensitivity or drug allergy.
- Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
- Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen
A Phase 2/3, Open-Label Multi- Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a Tenofovir Disoproxil Fumarate (TDF)-Containing Regimen, Initial Version, June 23, 2014
- Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
- Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
- Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents
- At least 4 weeks old but younger than 18 years old
- Confirmed HIV-1 infection
- Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)